Ponciri Fructus Immaturus ethanol extract attenuates septic shock through inhibition of the STAT1 signaling pathway

Introduction

Inflammation is one of the defense responses against infection, tissue injury, and other harmful conditions (1, 2). The inflammatory response involves multifactorial functions mediated by the activation of signaling pathways that regulate the expression of inflammatory factors in resident tissue cells and immune cells (3). Although this plays a critical role in host defense that is vital to health, an uncontrolled inflammatory response can lead to various diseases, such as cancer, heart disease, diabetes, and sepsis (4).

Sepsis is a systemic response syndrome that results in organ dysfunction and death. Despite advances in medical care, the incidence and mortality of sepsis are increasing (5). Thus, sepsis is globally an important public health issue to overcome. During the onset of sepsis, the initial immune recognition response is mediated by innate immune cells such as macrophages and neutrophils (6, 7). Macrophages produce proinflammatory cytokines, such as intereukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, to diminish invaded pathogens (8, 9). Nevertheless, the excessive release of inflammatory cytokines can lead to systemic inflammation and multi-organ damage (10). Nitric oxide (NO) also play a critical role in the progression of sepsis and septic shock. The release of robust amounts of NO is associated with circulatory disorders in septic shock that can lead to microvascular dysfunction and cellular toxicity (11, 12). NO is released through the inducible nitric oxide synthase (iNOS). The activation of iNOS has been implicated in the synergistic induction of various inflammatory cytokines, such as IFN, TNF, IL-1β, and IL-6 (13). Accordingly, the regulation of these inflammatory cytokines and iNOS-induced NO release is important for treating septic and endotoxic shock.

Ponciri Fructus Immaturus (PFI) is the unripe fruit of Poncirus trifoliata Rafinesque of the Rutaceae family. Traditionally, PFI extracts (PFIEs) have been used to treat inflammation, digestive ulcers, gastritis, and dysentery in Korea and China (14, 15). PFI has a variety of pharmacological properties, such as antiallergy (16), anti-apoptosis (17), anti-obesity (18), anti-inflammatory (19), and memory-enhancing effects (20). PFIE can inhibit the development of testosterone-induced benign prostatic hyperplasia through its anti-proliferative and anti-oxidant effects (21). It also suppresses the invasion and migration of B16 melanoma cells (22) and hepatocellular carcinoma cells (23). It has recently been reported that PFIE improves insulin resistance by regulating macrophage-mediated inflammation and enhances glucose and lipid metabolism in high-fat diet-induced obese mice (24). Moreover, PFIE has shown strong anti-adipogenic activity by downregulating the adipogenic markers, such as peroxisome proliferator-activated receptors proteins γ, sterol response element binding proteins-1, and CCAAT/enhancer binding proteins α (25). However, the effects of PFI on sepsis remain unknown.

In the current study, we investigated the impact of PFIE on the inflammatory responses induced by LPS in J774 macrophage cells. We further evaluated its anti-septic effect using LPS- and cecal ligation and puncture (CLP)-induced mouse models of sepsis.

Materials and methods

Preparation of Ponciri Fructus Immaturus extracts

We obtained lyophilized powder prepared from 70% ethanol extract of PFI from KOC Biotech (cat. No. KOC-70E-312; Daejeon, South Korea). PFI powder was dissolved in 10% dimethyl sulfoxide (Sigma, St. Louis, MO, United States) to a final concentration of 50 mg/mL, filtered through a 0.22 μm membrane, and stored at −20°C.

Reagents and antibodies

LPS was obtained from Sigma. iNOS and β-actin antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, United States). phospho-IKKα/β, IKKα, phospho-IκBα, IκBα, phospho-STAT1, STAT1, phospho-STAT3, STAT3, and PARP antibodies were obtained from Cell Signaling Technology (Danvers, MA, United States).

Cell culture and treatment

The murine macrophage cell line J774 was obtained from the American Type Culture Collection (Rockville, MD, United States) and maintained in Dulbecco’s modified Eagle’s medium (Gibco, NY, United States) containing 10% FBS (HyClone, Logan, UT, United States) and antibiotics (100 U/mL penicillin and 100 μg/mL streptomycin; Gibco-BRL). The cells were incubated in a humidified incubator with 5% CO₂ at 37°C.

Animal experiments

C57BL/6 mice (aged 6–10 weeks) used in animal experiments were purchased from the Korea Research Institute of Bioscience and Biotechnology (KRIBB; Cheongju, South Korea), and maintained in a controlled room [specific-pathogen-free, constant temperature (23 ± 2°C) and humidity (50 ± 10%)], 12-h light/dark cycle (lights on at 8 a.m.) at the Animal Experiment Center of KRIBB. Mice were orally administered with 10 and 20 mg/kg PFIE dissolved in phosphate-buffered saline (PBS; 100 μL/mouse) or vehicle control (PBS; 100 μL/mouse) for 7 days. After 24 h, sepsis was induced in the mice using LPS or via CLP. For LPS-induced sepsis, mice were intraperitoneally injected with LPS (10 mg/kg; in 100 μL PBS) or vehicle control (PBS; 100 μL/mouse) and were divided into the following groups (n = 10 per group): (1) sham; (2) LPS + PBS; (3) LPS + 10 mg/kg PFIE; and (4) LPS + 20 mg/kg PFIE groups. CLP was performed as described by Oh et al. (9). The mice were divided into the following groups (n = 10 per group): (1) sham; (2) CLP + PBS; (3) CLP + 10 mg/kg PFIE; and (4) CLP + 20 mg/kg PFIE groups. They were anesthetized using 500 mg/kg of avertin by intraperitoneal injection. The cecum was exteriorized with forceps, ligated, and punctured with a 23-gauge needle. The cecal contents were then emptied into the abdominal cavity. The cecum was returned to the peritoneal cavity, and the abdomen and skin were closed with 6.0 silk sutures. After the surgical procedure, 1 mL of PBS was administered subcutaneously as a resuscitation solution to prevent postoperative hypotension. Mice in the sham group were subjected to the same surgery except for cecal ligation and puncture. Mice survival rate was monitored for 7 days after CLP and LPS injection, after which no further loss of mice occurred. The KRIBB Institutional Animal Care and Use Committee approved all animal experiments (KRIBB-AEC-21075).

Blood sample collection and analysis

Mice were orally administered with 10 and 20 mg/kg PFIE dissolved in PBS (100 μL/mouse) or vehicle control (PBS; 100 μL/mouse) for 7 days. After 24 h, mice (n = 5 per group) were subjected to LPS injection or CLP for 12 h. Blood samples were collected from mice via cardiac puncture after anesthesia with tribromoethanol (avertin; Sigma-Aldrich). The serum was collected by centrifugation at 2000 × g for 30 min and stored at −80°C for cytokine measurement.

Cell viability

Cell viability was measured by the water-soluble tetrazolium salt (WST)-1 assay (Roche Diagnostics) following the manufacturer’s instructions. Briefly, 1 × 10⁴ J774 cells were seeded in 96-well plates overnight and then treated with various concentrations of PFIE for 24 h, 10 μL of WST-1 reagent was added to each well and incubated for 1 h. The conversion of WST-1 reagent into chromogenic formazan was assessed using a microplate reader.

Measurement of nitric oxide production

Nitrate accumulation in the culture media or serum samples was considered an indicator of NO production. Total NO production was measured by mixing 100 μL of the culture medium or serum samples with an equal volume of Griess reagent (0.1% N-[1-naphthyl] ethylenediamine dihydrochloride and 1% sulfanilamide in 5% phosphoric acid) for 10 min. The absorbance at 562 nm was then measured using a microplate reader (Molecular Devices, San Jose, CA, United States). NO concentration was determined based on a sodium nitrite standard curve.

Cytokine measurement

The levels of TNF-α, IL-1β, and IL-6 were measured using a mouse TNF-α DuoSet ELISA kit (DY-410; R&D Systems), mouse IL-1β DuoSet ELISA kit (DY-401; R&D Systems), and mouse IL-6 DuoSet ELISA kit. (DY-406; R&D Systems), respectively. All ELISAs were performed following the manufacturer’s instructions.

Western blotting

The cells were solubilized in radioimmunoprecipitation assay lysis buffer with protease inhibitor cocktail (Sigma). Obtained proteins (10–30 μg) were separated using 8–15% sodium dodecyl sulfate (SDS)–polyacrylamide electrophoresis (PAGE) and then transferred to polyvinylidene difluoride (PVDF) membranes (Trans-Blot Turbo Transfer pack; Bio-Rad, Hercules, CA, United States). Subsequently, the membranes were incubated for 2 h in 5% skimmed milk/TBS-T buffer (Phosphate-buffered saline, with 5% powdered milk and 1% Triton X-100), probed with primary antibodies at 4°C overnight, and subsequently incubated for 1 h at room temperature with horseradish peroxidase-conjugated secondary antibodies. The membranes were developed with enhanced chemiluminescence reaction according to the manufacturer’s instructions.

Quantitative real-time polymerase chain reaction analysis

Total RNA was extracted from the cultured cells using TRIzol RNA Isolation Reagents (Invitrogen, CA, United States) following the manufacturer’s instructions. Reverse transcription was performed using 10 μg of total RNA with a reverse transcription kit (Promega, WI, United States). Quantitative Real-Time PCR was performed using the QuantStudio 3 system (Thermo, Waltham, MA, United States). The expression of TNF-α, IL-1β, and IL-6 was assayed in a total volume of 20 μL containing AccuPower^® 2X GreenStar™ qPCR Master Mix (Bioneer, Daedeok-gu, Daejeon, South Korea) according to the manufacturer’s instructions. Relative mRNA levels were calculated using the 2^–ΔΔCt method. Duplicate measurements were made for each sample, and each group had at least three samples. The expression (Ct value) of GAPDH was not significantly different among all groups. The primer used were: iNOS(F), 5′-CAAGCACCTTGGAAGAGGAG-3′; iNOS(R), 5′-AAGGCCAAACACAGCATACC-3′; TNF-α(F), 5′-ACGG CATGGATCTCAAAGAC-3′; TNF-α(R), 5′-TGAGATAGCAA ATCG GCTGAC-3′; IL-1β(F), 5′-GAGTGTGGATCCCA AGCAAT-3′; IL-1β(R), 5′-CTTGTGCTCTGCT TGTGAGG-3′; IL-6(F), 5′-CTGATGCTGGTGACAACCAC-3′; IL-6(R), 5′-TCC ACGATTTCCCA GAGAAC-3′; GAPDH(F), 5′-ACCCAGAAGACTGTGGATGG-3′; and GAPDH(R), 5′-ACACATTG GGGGTAGGAACA-3′.

Statistical analysis

Quantitative data are expressed using the mean ± standard deviation and analyzed by a 2-tailed unpaired Student t-test to compare the difference between groups. When the P-value was <0.05, the differences between groups were statistically significant.

Results

PFIE suppresses LPS-Induced NO production by inhibiting iNOS expression in J774 macrophages

To determine the optimal concentration of PFIE, J774 macrophages were treated with varying concentrations of PFIE (10, 20, 50, and 100 μg/mL) for 24 h. PFIE decreased J774 cell viability at concentrations of 50 μg/mL but had no effect at concentrations below 20 μg/mL (Figure 1A). Therefore, the concentration of PFIE was determined below 20 μg/mL for subsequent experiments. NO is a major pro-inflammatory mediator that is overproduced in abnormal situations, thereby inducing inflammation (12). To investigate this, J774 cells were primed with the indicated concentrations of PFIE for 1 h and then treated with 1 μg/mL LPS. LPS treatment resulted in significant upregulation of NO metabolites, and this induction was significantly suppressed in PFIE-treated J774 cells in a concentration-dependent manner (Figure 1B). Furthermore, real-time PCR and western blot analysis showed that LPS induced the mRNA and protein expression of iNOS, whereas PFIE pretreatment suppressed this induction in a dose-dependent manner (Figures 1C,D). These results suggest that PFIE attenuates the LPS-induced production of the inflammatory mediator NO by inhibiting the expression of iNOS in J774 cells.

FIGURE 1

Figure 1. PFIE suppresses LPS-induced NO production and iNOS expression in J774 macrophages. (A) Effect of PFIE on J774 cell viability was determined using WST-1 assay. (B) NO levels in culture media were measured using Griess reagent. (C) mRNA levels of iNOS were analyzed using real-time PCR. Relative mRNA expression levels were normalized to those of GAPDH. *P < 0.05, **P < 0.01, and ^#P < 0.001 (Student’s t-test). Data are representative of three experiments. (D) Protein levels of iNOS were analyzed via immunoblotting.

PFIE suppresses the production of proinflammatory cytokines in LPS-stimulated J774 cells

Next, we assessed the mRNA levels of the proinflammatory cytokines TNF-α, IL-1β, and IL-6. Real-time RT-PCR data showed that mRNA expression of TNF-α (Figure 2A), IL-1β (Figure 2B), and IL-6 (Figure 2C) increased in LPS-stimulated J774 cells, and this LPS-induced expression was attenuated by PFIE in a concentration-dependent manner. We then determined the levels of TNF-α, IL-1β, and IL-6 in the culture media using ELISA and found that these molecules were significantly upregulated in the culture media of LPS-treated J774 cells compared with that of unstimulated control J774 cells. However, PFIE significantly suppressed the production of these cytokines in a dose-dependent manner (Figures 2D–F). These data suggest that PFIE suppresses the LPS-induced production of proinflammatory cytokines in J774 cells.

FIGURE 2

Figure 2. PFIE suppresses the production of inflammatory cytokines by LPS in J774 cells. Indicated PFIE concentrations were used for pretreatment 1 h prior to treatment with 1 μg/mL of LPS for 24 h. mRNA levels of panels (A) TNF-α, (B) IL-1β, and (C) IL-6 were determined using real-time PCR. Relative mRNA expression levels were normalized to those of GAPDH. (D–F) Secreted levels of panel (D) TNF-α, (E) IL-1β, and (F) IL-6 in the culture medium were measured using ELISA. *P < 0.05, **P < 0.01, and ^#P < 0.001 (Student’s t-test). Data are representative of three experiments.

PFIE suppresses STAT1 activation mediated by LPS stimulation in J774 cells

The signaling pathway by which PFIE regulates the production of proinflammatory mediators in LPS-stimulated J774 cells is unclear. Since the LPS-induced inflammatory responses are dependent on STAT and NF-κB activity (26), we investigated the relevance of these transcription mediators on the anti-inflammatory effects of PFIE. Western blot analysis showed that there is no significant difference in the phosphorylation of IKKα/β and IκBα between LPS-treated J774 cells in the presence or absence of PFIE (Figure 3A). We next investigated whether PFIE regulated the activation of STAT1 and STAT3. STAT1 phosphorylation was observed at 4 h and was markedly increased at 8 h after LPS treatment; however, PFIE inhibited STAT1 phosphorylation in LPS-stimulated cells (Figure 3B). Meanwhile, no difference was observed in the phosphorylation of STAT3 in LPS-stimulated J774 cells with or without PFIE (Figure 3B). Moreover, LPS stimulation enhanced nuclear level of pSTAT1, which was reduced by PFIE (Figure 3C). These findings indicate that PFIE suppresses LPS-induced STAT1 activation in J774 cells.

FIGURE 3

Figure 3. PFIE inhibits LPS-induced STAT1 activation in J774 macrophages. (A) IKKα/β and IκBα and (B) STAT1 and STAT2 phosphorylation in LPS-stimulated J774 cells in the presence or absence of PFIE was examined using immunoblotting. (C) pSTAT1 in the cytosol and nuclear fraction was examined using immunoblotting. PARP and β-actin were used as a nuclear and cytosolic fraction loading control, respectively.

PFIE improves the survival rate and suppresses the inflammatory response in an LPS- and CLP-induced mouse model of sepsis

LPS is a pathogen-associated molecular pattern that causes septic shock (9, 27). Because PFIE suppresses LPS-induced inflammatory responses in vitro, we investigated its effect on LPS-induced sepsis. Mice were orally administered with 10 or 20 mg/kg PFIE for 7 days, and septic shock was induced via injection of 10 mg/kg LPS. The survival rates of mice were monitored for 7 days. The overall survival rate was 20% in the LPS-treated mice. In contrast, the survival rate of mice in the LPS plus 10 or 20 mg/kg PFIE-treated mice was higher (40 and 60%, respectively) than that observed in the LPS-treated mice (Figure 4A). In addition, the serum levels of AST, ALT, and CK were reduced in the PFIE-treated groups (Figures 4B–D). Meanwhile, PFIE administration restored the decreased serum glucose levels induced by LPS (Figure 4E). Next, we examined the serum level of an inflammatory mediator NO in LPS-induced septic mice. LPS treatment increased NO serum level, which was reduced by PFIE (Figure 4F). Next, we examined the serum levels of the inflammatory cytokines, including TNF-α (Figure 4G), IL-1β (Figure 4H), and IL-6 (Figure 4I). The serum levels of TNF-α, IL-1β, and IL-6 significantly increased in LPS-treated mice. In contrast, PFIE treatment markedly decreased the LPS-induced serum levels of TNF-α, IL-1β, and IL-6 in a concentration-dependent manner.

FIGURE 4

Figure 4. PFIE prevents septic shock and attenuates proinflammatory responses in an LPS-induced endotoxemia mouse model. (A) Mortality was monitored for 7 days after LPS injection in the groups (n = 10): PBS (circle); LPS (triangle); LPS + 10 mg/kg of PFIE (inverted triangle); and LPS + 20 mg/kg of PFIE (diamond). (B–I) Mouse serum samples (n = 5) were collected 12 h after LPS injection. Serum levels of AST (B), ALT (C), and CK (D) measured using an automatic chemical analyzer. (F) Serum levels of nitric oxide (NO) metabolites measured using Griess reagent. The levels of TNF-α (G), IL-1β (H), and IL-6 (I) measured using ELISA. *P < 0.05, **P < 0.01, and ^#P < 0.001 (Student’s t-test).

We further investigated the effects of PFIE administration on the survival of septic mice using a CLP-induced septic mice model. Mice were orally administered with 10 or 20 mg/kg PFIE for 7 days and were then subjected to CLP. The survival rates of mice were monitored for 7 days. Similar to that observed with the LPS-induced model, the survival rates of PFIE-treated groups were significantly higher than those of the CLP-induced septic mice, and this increase occurred in a concentration-dependent manner (Figure 5A). PFIE administration decreased AST, ALT, and CK serum levels, which were enhanced by CLP (Figures 5B–D). Moreover, the serum levels of glucose were partially restored in the PFIE-treated groups compared with those in the CLP-only group (Figure 5E). We next assessed the effect of PFIE on the production of inflammatory factors in CLP-induced septic mice. PFIE administration markedly reduced the serum levels of NO (Figure 5F), TNF-α (Figure 5G), IL-1β (Figure 5H), and IL-6 (Figure 5I) in CLP-induced septic mice. These findings indicate that PFIE enhances the survival of LPS- and CLP-induced septic mice by suppressing inflammatory responses.

FIGURE 5

Figure 5. PFIE improves the survival rate and attenuates proinflammatory responses in a CLP-induced septic mouse model. (A) Mortality was monitored for 7 days after the surgery (n = 10): sham (circle); CLP (triangle); CLP + 10 mg/kg of PFIE (inverted triangle); CLP + 20 mg/kg of PFIE (diamond). (B–I) Mouse serum samples (n = 5) were collected 12 h after CLP. Serum levels of AST (B), ALT(C), and CK (D) measured using an automatic chemical analyzer. (F) Serum levels of nitric oxide (NO) metabolites measured using Griess reagent. Serum levels of TNF-α (G), IL-1β (H), and IL-6 (I) measured using ELISA. *P < 0.05 and **P < 0.01 (Student’s t-test).

Discussion

Inflammation is a complex biological response to noxious stimuli, such as foreign pathogens or tissue damage (1). The inflammatory response is important for host defenses against infection. However, abnormal activation of innate immune cells can lead to sepsis, a systemic response syndrome resulting in organ dysfunction and death (28). Despite advances in medical care, the incidence and mortality of sepsis are increasing. Thus, sepsis is a severe public health problem to overcome worldwide. Therefore, it is necessary to develop efficient antiseptic therapeutics for patients with sepsis. PFI has various pharmacological properties such as antiallergy, antitumor, and anti-inflammatory effects. Although many studies have investigated the pharmacological effects of PFIE on various diseases, its effects on the underlying mechanisms of the pathogenesis of sepsis are unclear. Here, we demonstrated the antiseptic effect of PFIE in vivo using LPS- and CLP-induced mouse models of sepsis. PFIE administration improved the survival rate of LPS- and CLP-induced septic mice. AST, ALT, and CK serum levels are typically elevated in inflammatory shock conditions, and their high serum levels may be a sign of liver injury. Also, an imbalance of glucose in the blood and tissues is one of the hallmarks of sepsis. Therefore, controlling blood glucose levels is one of the vital treatments for sepsis (5, 29). Our data showed that the serum levels of ALT, AST, and CK were significantly reduced by PFIE treatment in LPS- and CLP-induced septic mice, which indicates that it suppressed endotoxin- and CLP-induced liver damage. Moreover, the serum level of glucose decreased by LPS- and CLP-induced septic shock was returned to normal levels by PFIE. These findings indicate the therapeutic potential of PFIE for sepsis.

Sepsis is associated with excessive activation of the innate immune system. Macrophages and neutrophils play critical roles in regulating cytokine-mediated inflammatory responses against infection (6). Macrophage-mediated proinflammatory responses to infection generally allow pathogen clearance with minimal tissue damage and remodeling. However, the uncontrolled inflammatory response of macrophages causes excessive cytokine production, which can lead to local and systemic inflammation (30). TNF-α is a critical mediator of immune response to sepsis. TNF-α levels are elevated in patients with septic shock and are associated with clinical outcomes (10). IL-1 and IL-6 are also important inflammatory cytokines in sepsis. Their excessive production is correlated with hypotension, multiorgan failure, and mortality in septic patients (8, 10). NO also is a critical mediator of the progression of sepsis. The excessive production of NO causes microvascular dysfunction and cellular toxicity (12). In the present study, we showed the anti-inflammatory effect of PFIE in endotoxin-treated macrophages and septic mouse models. PFIE suppressed the production of NO, IL-1β, TNF-α, and IL-6 in LPS-stimulated J774 cells. In addition, we extended this analysis in vivo using the LPS- and CLP-induced mouse model of sepsis. PFIE administration suppressed the production of NO, IL-1β, TNF-α, and IL-6 in LPS- and CLP-induced septic mice. Therefore, PFIE is predicted to suppress dysfunctional inflammatory responses by macrophages and protect against the detrimental effects of sepsis. Since the possibility that PFIE may modulate inflammatory responses by other immune cells in sepsis cannot be excluded, further research is needed to elucidate the relationship with other immune cells, such as neutrophils, in the anti-septic efficacy of PFIE.

PFI is widely used in traditional medicine for edema, dyspepsia, and cardiovascular diseases (14). PFI has various pharmacological properties such as antiallergy, antitumor, antiviral, and anti-inflammatory effects (16–20). PFI contains high amounts of various compounds, including flavonoids (naringin, neoponcirin, and poncirin) and coumarins (umbelliferone, imperatorin, and auraptene), which have various pharmacological activities, including anticancer and anti-inflammatory effects (24, 25). Naringin exhibited anti-inflammatory, antioxidant, and antiapoptotic effects in treating LPS-induced cardiac injury (31, 32). Poncirin suppressed the LPS-induced production of inflammatory cytokines TNF-α and IL-6 in RAW 264.7 macrophages and attenuated ischemic injury in stroke mice (33, 34). Auraptene suppressed inflammatory responses by inhibiting LPS-induced p38 activation in RAW 264.7 macrophages and ameliorated neuronal cell death in the LPS-induced Parkinson’s disease mouse model (35, 36). Umbelliferone prevented testicular injury by suppressing oxidative damage and inflammation in diabetic rats (37). Imperatorin mitigated cardiac dysfunction by modulating inflammation and oxidative stress in high-fat diet rats (38). It also attenuated the inflammation associated with synovial fibrosis by suppressing the production of proinflammatory cytokines and mediators (39). Therefore, the anti-inflammatory properties of PFIE during sepsis are based on various pharmacological activities.

NF-κB and STAT1 are vital in inflammatory and immune responses (40). NF-κB signaling pathway is activated in peripheral mononuclear cells and alveolar macrophages of sepsis patients, which is highly correlated with the progression of sepsis (41). STAT1 is also a critical transcription factor involved in many physiological functions, including the response to infection. STAT1 activation is required to produce interferons, which trigger the JAK/STAT signaling pathway in an autocrine or paracrine manner. In septic mouse models, STAT1 activity is significantly elevated in macrophages (42, 43). Although several flavonoids inhibit the production of proinflammatory cytokines by suppressing NF-κB activity (44). Oroxylin A, a flavonoid isolated from Scutellaria baicalensi, attenuates the expression of proinflammatory cytokines by suppressing the JAK/STAT1 pathway without affecting NF-κB activity (45). Consistent with this result, we showed that PFIE suppressed the activation of STAT1, but not NF-κB, and sequentially reduced the LPS-induced production of inflammatory cytokines in J774 cells. These findings suggest that the anti-inflammatory effects of PFIE are attributable, at least in part, to the inhibition of STAT1 activity.

Conclusion

In summary, we revealed for the first time the anti-septic potential of PFI extract and its molecular signaling pathway (Figure 6). The findings of this study showed that PFIE attenuated the LPS-induced inflammatory responses in J774 macrophage cells, which might be related to the inhibition of STAT1 signaling. Moreover, PFIE administration ameliorated experimental sepsis in mice by suppressing the production of inflammatory cytokines and mediators. This study demonstrates the role of PFIE as a promising therapeutic candidate in treating acute inflammatory disease.

FIGURE 6

Figure 6. The possible inhibitory pathways of PFIE in sepsis.

Data availability statement

The original contributions presented in this study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

The animal study was reviewed and approved by the KRIBB Institutional Animal Care and Use Committee.

Author contributions

YH and J-PJ: conceptualization. YH, J-PJ, AK, and HY: methodology. J-HJ: formal analysis. YH, J-PJ, HY, and SY: investigation. JP and S-HP: data curation. YH and JP: writing—original draft preparation. JP, HC, and HL: writing—review and editing and supervision. HC and HL: project administration. All authors contributed to the article and approved the submitted version.

Funding

This research was supported by the R&D Convergence Program (CAP21021-200) and KRIBB Research Initiative Program (1711170625).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Medzhitov R. Origin and physiological roles of inflammation. Nature. (2008) 454:428–35. doi: 10.1038/nature07201

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. (2018) 9:7204–18. doi: 10.18632/oncotarget.23208

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. (2010) 140:805–20. doi: 10.1016/j.cell.2010.01.022

PubMed Abstract | CrossRef Full Text | Google Scholar

4. Doganyigit Z, Eroglu E, Akyuz E. Inflammatory mediators of cytokines and chemokines in sepsis: From bench to bedside. Hum Exp Toxicol. (2022) 41:9603271221078871. doi: 10.1177/09603271221078871

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. (2018) 392:75–87. doi: 10.1016/S0140-6736(18)30696-2

CrossRef Full Text | Google Scholar

6. Lambden S. Bench to bedside review: Therapeutic modulation of nitric oxide in sepsis-an update. Intensive Care Med Exp. (2019) 7:64. doi: 10.1186/s40635-019-0274-x

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Thompson K, Venkatesh B, Finfer S. Sepsis and septic shock: Current approaches to management. Intern Med J. (2019) 49:160–70. doi: 10.1111/imj.14199

PubMed Abstract | CrossRef Full Text | Google Scholar

8. Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med. (2003) 9:517–24. doi: 10.1038/nm0503-517

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Oh BM, Lee SJ, Park GL, Hwang YS, Lim J, Park ES, et al. Erastin inhibits septic shock and inflammatory gene expression via suppression of the NF-kappaB pathway. J Clin Med. (2019) 8:2210. doi: 10.3390/jcm8122210

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Fujishima S. Organ dysfunction as a new standard for defining sepsis. Inflamm Regen. (2016) 36:24. doi: 10.1186/s41232-016-0029-y

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Winkler MS, Kluge S, Holzmann M, Moritz E, Robbe L, Bauer A, et al. Markers of nitric oxide are associated with sepsis severity: An observational study. Crit Care. (2017) 21:189. doi: 10.1186/s13054-017-1782-2

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am J Respir Crit Care Med. (2000) 161:1781–5. doi: 10.1164/ajrccm.161.6.9812004

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Kim KM, Kim SY, Mony TJ, Bae HJ, Han SD, Lee ES, et al. Dracocephalum moldavica ethanol extract suppresses LPS-induced inflammatory responses through inhibition of the JNK/ERK/NF-kappaB signaling pathway and IL-6 production in RAW 264.7 macrophages and in endotoxic-treated mice. Nutrients. (2021) 13:4501. doi: 10.3390/nu13124501

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Lee YM, Kim DK, Kim SH, Shin TY, Kim HM. Antianaphylactic activity of Poncirus trifoliata fruit extract. J. Ethnopharmacol. (1996) 54:77–84. doi: 10.1016/S0378-8741(96)01451-1

CrossRef Full Text | Google Scholar

15. Shin TY, Oh JM, Choi BJ, Park WH, Kim CH, Jun CD, et al. Antiinflammatory effect of Poncirus trifoliata fruit through inhibition of NF-B activation in mast cells. Toxicol Vitro. (2006) 20:1071–6. doi: 10.1016/j.tiv.2006.02.003

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Kim HM, Kim HJ, Park ST. Inhibition of immunoglobulin E production by Poncirus trifoliata fruit extract. J Ethnopharmacol. (1999) 66:283–8. doi: 10.1016/S0378-8741(99)00028-8

CrossRef Full Text | Google Scholar

17. Zhao L, Zhang W, Zhang F. Poncirin downregulates ATP-binding cassette transporters to enhance cisplatin sensitivity in cisplatin-resistant osteosarcoma cells. Phytother Res. (2021) 35:278–88. doi: 10.1002/ptr.6798

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Shim WS, Back H, Seo EK, Lee HT, Shim CK. Long-term administration of an aqueous extract of dried, immature fruit of Poncirus trifoliata (L.) Raf. suppresses body weight gain in rats. J Ethnopharmacol. (2009) 126:294–9. doi: 10.1016/j.jep.2009.08.022

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Shin EM, Zhou HY, Xu GH, Lee SH, Merfort I, Kim YS. Anti-inflammatory activity of hispidol A 25-methyl ether, a triterpenoid isolated from Ponciri Immaturus Fructus. Eur J Pharmacol. (2010) 627:318–24. doi: 10.1016/j.ejphar.2009.10.036

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Kim JK, Choi SJ, Bae H, Kim CR, Cho HY, Kim YJ, et al. Effects of methoxsalen from Poncirus trifoliata on acetylcholinesterase and trimethyltin-induced learning and memory impairment. Biosci Biotechnol Biochem. (2011) 75:1984–9. doi: 10.1271/bbb.110386

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Jeon WY, Kim OS, Seo CS, Jin SE, Kim JA, Shin HK, et al. Inhibitory effects of Ponciri fructus on testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Altern Med. (2017) 17:384. doi: 10.1186/s12906-017-1877-y

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Kim SY, Choi IH, Han MJ, Yi HK, Yun BS, Park HR, et al. In vitro mitochondrial apoptosis of melanoma cells via immature Poncirus trifoliata fruit extract. Eur Rev Med Pharmacol Sci. (2022) 26:5380–92. doi: 10.26355/eurrev_202208_29405

CrossRef Full Text | Google Scholar

23. Munakarmi S, Chand L, Shin HB, Hussein UK, Yun BS, Park HR, et al. Anticancer effects of Poncirus fructus on hepatocellular carcinoma through regulation of apoptosis, migration, and invasion. Oncol Rep. (2020) 44:2537–46. doi: 10.3892/or.2020.7790

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Kim M, Seol MH, Lee BC. The effects of Poncirus fructus on insulin resistance and the macrophage-mediated inflammatory response in high fat diet-induced obese mice. Int J Mol Sci. (2019) 20:2858. doi: 10.3390/ijms20122858

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Lamichhane G, Pandeya PR, Lamichhane R, Rhee SJ, Devkota HP, Jung HJ. Anti-obesity potential of Ponciri Fructus: Effects of extracts, fractions and compounds on adipogenesis in 3T3-L1 preadipocytes. Molecules. (2022) 27:676. doi: 10.3390/molecules27030676

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, et al. Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK/NF-kappaB, MKK7/JNK, and JAK2/STAT1 signalling pathways. J Immunol Res. (2021) 2021:9944880. doi: 10.1155/2021/9944880

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. (2009) 22:240–73. doi: 10.1128/CMR.00046-08

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Crouser E, Exline M, Knoell D, Wewers MD. Sepsis: Links between pathogen sensing and organ damage. Curr Pharm Des. (2008) 14:1840–52. doi: 10.2174/138161208784980572

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Usmani J, Khan T, Ahmad R, Sharma M. Potential role of herbal medicines as a novel approach in sepsis treatment. Biomed Pharmacother. (2021) 144:112337. doi: 10.1016/j.biopha.2021.112337

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Tang XD, Ji TT, Dong JR, Feng H, Chen FQ, Chen X, et al. Pathogenesis and treatment of cytokine storm induced by infectious diseases. Int J Mol Sci. (2021) 22:13009. doi: 10.3390/ijms222313009

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Kanno S, Shouji A, Tomizawa A, Hiura T, Osanai Y, Ujibe M, et al. Inhibitory effect of naringin on lipopolysaccharide (LPS)-induced endotoxin shock in mice and nitric oxide production in RAW 264.7 macrophages. Life Sci. (2006) 78:673–81. doi: 10.1016/j.lfs.2005.04.051

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Xianchu L, Lan PZ, Qiufang L, Yi L, Xiangcheng R, Wenqi H, et al. Naringin protects against lipopolysaccharide-induced cardiac injury in mice. Environ Toxicol Pharmacol. (2016) 48:1–6. doi: 10.1016/j.etap.2016.09.005

PubMed Abstract | CrossRef Full Text | Google Scholar

33. Kim JB, Han AR, Park EY, Kim JY, Cho W, Lee J, et al. Inhibition of LPS-induced iNOS, COX-2 and cytokines expression by poncirin through the NF-kappaB inactivation in RAW 264.7 macrophage cells. Biol Pharm Bull. (2007) 30:2345–51. doi: 10.1248/bpb.30.2345

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Yang LX, Chen FY, Yu HL, Liu PY, Bao XY, Xia SN, et al. Poncirin suppresses lipopolysaccharide (LPS)-induced microglial inflammation and ameliorates brain ischemic injury in experimental stroke in mice. Ann Transl Med. (2020) 8:1344. doi: 10.21037/atm-20-3470

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Lin S, Hirai S, Goto T, Sakamoto T, Takahashi N, Yano M, et al. Auraptene suppresses inflammatory responses in activated RAW264 macrophages by inhibiting p38 mitogen-activated protein kinase activation. Mol Nutr Food Res. (2013) 57:1135–44. doi: 10.1002/mnfr.201200611

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Okuyama S, Semba T, Toyoda N, Epifano F, Genovese S, Fiorito S, et al. Auraptene and other prenyloxyphenylpropanoids suppress microglial activation and dopaminergic neuronal cell death in a lipopolysaccharide-induced model of Parkinson’s disease. Int J Mol Sci. (2016) 17:1716. doi: 10.3390/ijms17101716

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Allam MAM, Khowailed AA, Elattar S, Mahmoud AM. Umbelliferone ameliorates oxidative stress and testicular injury, improves steroidogenesis and upregulates peroxisome proliferator-activated receptor gamma in type 2 diabetic rats. J Pharm Pharmacol. (2022) 74:573–84. doi: 10.1093/jpp/rgab083

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Prasartthong P, Pakdeechote P, Maneesai P, Meephat S, Rattanakanokchai S, Wunpathe C, et al. Imperatorin attenuates cardiac remodelling and dysfunction in high-fat/high-fructose diet-fed rats by modulating oxidative stress, inflammation, and Nrf-2 expression. Tissue Cell. (2022) 75:101728. doi: 10.1016/j.tice.2021.101728

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Zhang H, Ding L, Shi X, Mei W, Huang Z, Zhang L, et al. Imperatorin alleviated NLR family pyrin domain-containing 3 inflammasome cascade-induced synovial fibrosis and synovitis in rats with knee osteoarthritis. Bioengineered. (2021) 12:12954–64. doi: 10.1080/21655979.2021.2012949

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Platanitis E, Decker T. Regulatory networks involving STATs, IRFs, and NFkappaB in inflammation. Front Immunol. (2018) 9:2542. doi: 10.3389/fimmu.2018.02542

PubMed Abstract | CrossRef Full Text | Google Scholar

41. Barnes PJ, Karin M. Nuclear factor-kappaB: A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. (1997) 336:1066–71. doi: 10.1056/NEJM199704103361506

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Toshchakov V, Jones BW, Perera PY, Thomas K, Cody MJ, Zhang S, et al. TLR4, but not TLR2, mediates IFN-beta-induced STAT1alpha/beta-dependent gene expression in macrophages. Nat Immunol. (2002) 3:392–8. doi: 10.1038/ni774

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Jacobs AT, Ignarro LJ. Lipopolysaccharide-induced expression of interferon-beta mediates the timing of inducible nitric-oxide synthase induction in RAW 264.7 macrophages. J Biol Chem. (2001) 276:47950–7. doi: 10.1074/jbc.M106639200

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Kim HP, Son KH, Chang HW, Kang SS. Anti-inflammatory plant flavonoids and cellular action mechanisms. J Pharmacol Sci. (2004) 96:229–45. doi: 10.1254/jphs.crj04003x

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Liu PW, Chen MF, Tsai AP, Lee TJ. STAT1 mediates oroxylin a inhibition of iNOS and pro-inflammatory cytokines expression in microglial BV-2 cells. PLoS One. (2012) 7:e50363. doi: 10.1371/journal.pone.0050363

PubMed Abstract | CrossRef Full Text | Google Scholar